A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

Trial ID or NCT#

NCT02576431

Status

not recruiting iconNOT RECRUITING

Purpose

This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer.

Official Title

A Study to Learn How Well the Drug Larotrectinib Works in Adults With Different Solid Cancers With a Change in the Genes Called NTRK Fusion

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Saad A. Khan
Saad A. Khan
Medical oncologist
Associate Professor of Medicine (Oncology)

Contact us to find out if this trial is right for you.

Contact

Aja Marcias
650-497-7499

View on ClinicalTrials.gov